Your browser is no longer supported. Please, upgrade your browser.
Settings
BLPH Bellerophon Therapeutics, Inc. daily Stock Chart
BLPH [NASD]
Bellerophon Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.82 Insider Own2.30% Shs Outstand4.62M Perf Week5.08%
Market Cap116.48M Forward P/E- EPS next Y-1.32 Insider Trans3.96% Shs Float4.24M Perf Month2.28%
Income-17.40M PEG- EPS next Q-0.72 Inst Own16.10% Short Float8.97% Perf Quarter30.71%
Sales- P/S- EPS this Y-554.00% Inst Trans-22.77% Short Ratio1.14 Perf Half Y151.17%
Book/sh0.47 P/B28.62 EPS next Y49.40% ROA-112.80% Target Price- Perf Year43.24%
Cash/sh- P/C- EPS next 5Y- ROE-284.20% 52W Range3.19 - 26.00 Perf YTD156.41%
Dividend- P/FCF- EPS past 5Y47.70% ROI- 52W High-48.27% Beta-0.71
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin- 52W Low322.17% ATR0.80
Employees18 Current Ratio1.30 Sales Q/Q- Oper. Margin- RSI (14)49.53 Volatility6.73% 6.08%
OptionableNo Debt/Eq0.00 EPS Q/Q-488.80% Profit Margin- Rel Volume0.76 Prev Close12.96
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume334.75K Price13.45
Recom2.00 SMA204.18% SMA50-7.47% SMA20049.26% Volume255,383 Change3.78%
Jan-24-19Initiated Maxim Group Buy $3
Apr-17-17Initiated Ladenburg Thalmann Buy $4.50
Jan-20-17Initiated H.C. Wainwright Buy $5
Mar-22-16Reiterated Leerink Partners Outperform $11 → $9
Jul-27-15Reiterated FBR Capital Outperform $23 → $11
Mar-16-15Initiated FBR Capital Outperform $23
Jun-29-20 08:00AM  
Jun-04-20 06:42PM  
May-29-20 03:40PM  
May-22-20 09:47AM  
May-19-20 06:53PM  
07:00AM  
May-18-20 04:03PM  
May-12-20 10:09AM  
May-11-20 04:01PM  
08:30AM  
May-04-20 08:30AM  
Apr-17-20 12:19PM  
Apr-08-20 08:23PM  
08:30AM  
Apr-06-20 10:23AM  
Apr-01-20 01:06PM  
Mar-31-20 08:30AM  
Mar-30-20 09:57AM  
08:00AM  
Mar-29-20 03:44PM  
Mar-23-20 09:30AM  
Mar-22-20 08:19AM  
Mar-20-20 08:30AM  
Mar-10-20 08:30AM  
Feb-21-20 12:11PM  
Feb-19-20 10:32AM  
09:21AM  
07:21AM  
Feb-18-20 08:30AM  
Feb-07-20 12:00PM  
Dec-20-19 04:18PM  
Dec-17-19 08:44AM  
07:00AM  
Nov-12-19 08:30AM  
Nov-07-19 08:30AM  
Nov-06-19 08:30AM  
Nov-01-19 11:51AM  
Oct-28-19 07:15AM  
Oct-23-19 08:30AM  
07:54AM  
Oct-20-19 08:08AM  
Oct-14-19 08:30AM  
Sep-16-19 08:30AM  
Sep-04-19 08:30AM  
Aug-08-19 12:57PM  
08:30AM  
Aug-06-19 08:15PM  
Aug-01-19 08:30AM  
Jun-13-19 08:00AM  
May-22-19 08:30AM  
May-21-19 08:30AM  
May-18-19 09:50AM  
May-13-19 08:30AM  
May-09-19 08:45AM  
08:30AM  
May-03-19 12:10PM  
Apr-08-19 08:30AM  
Mar-18-19 02:08PM  
Mar-14-19 09:09AM  
08:30AM  
Jan-28-19 08:30AM  
Jan-25-19 04:05PM  
Jan-23-19 06:00AM  
Jan-22-19 04:44PM  
Jan-07-19 08:30AM  
Nov-21-18 08:55AM  
Nov-16-18 01:32AM  
Nov-07-18 09:36AM  
08:30AM  
Oct-09-18 08:30AM  
Sep-10-18 11:40AM  
Aug-29-18 08:00AM  
Aug-20-18 08:00AM  
Aug-08-18 08:15AM  
Aug-07-18 08:30AM  
Aug-01-18 09:16AM  
08:40AM  
Jun-15-18 09:13AM  
Jun-12-18 08:39AM  
08:00AM  
Jun-11-18 12:45PM  
09:08AM  
May-16-18 08:30AM  
May-10-18 08:45AM  
May-08-18 08:30AM  
Apr-30-18 08:43AM  
Apr-19-18 09:35AM  
Apr-03-18 08:30AM  
Mar-27-18 07:00AM  
Mar-23-18 10:56AM  
Mar-15-18 07:17PM  
04:45PM  
Jan-29-18 08:30AM  
Jan-03-18 08:30AM  
Nov-30-17 05:46PM  
Nov-07-17 08:43AM  
08:30AM  
Sep-27-17 08:30AM  
Sep-07-17 04:01PM  
Sep-05-17 08:40AM  
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wang Theodore TDirectorJun 08Buy12.872,60033,45460,913Jun 09 04:01 PM
Wang Theodore TDirectorJun 05Buy12.724,98663,44258,313Jun 09 04:01 PM
Wang Theodore TDirectorNov 25Buy0.397,1932,774592,922Nov 25 04:52 PM
Wang Theodore TDirectorNov 22Buy0.371,050394585,729Nov 25 04:52 PM
Wang Theodore TDirectorNov 21Buy0.3720074584,679Nov 25 04:52 PM
VENROCK ASSOCIATES IV L P10% OwnerOct 28Sale0.44333,010146,0916,435,173Oct 28 05:17 PM
VENROCK ASSOCIATES IV L P10% OwnerOct 28Sale0.44333,010146,0916,435,173Oct 28 05:15 PM
VENROCK ASSOCIATES IV L P10% OwnerOct 25Sale0.4556,24225,5116,768,183Oct 28 05:17 PM
VENROCK ASSOCIATES IV L P10% OwnerOct 25Sale0.4556,24225,5116,768,183Oct 28 05:15 PM
VENROCK ASSOCIATES IV L P10% OwnerOct 24Sale0.50704,595353,3546,824,425Oct 28 05:17 PM
VENROCK ASSOCIATES IV L P10% OwnerOct 24Sale0.50704,595353,3546,824,425Oct 28 05:15 PM